stockrow
Monday 9 November 2026
Export TXMD’s income statement to Excel — free account
TherapeuticsMD, Inc.
TXMDHealthcare Drug Manufacturers Specialty & Generic
TherapeuticsMD, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 million, up 71.6% from fiscal 2024.
- Revenue
- −8.72%
- EPS
- −80.0%
- Free cash flow
- +104.5%
Quarter to June 2026, against a year earlier
1.74
0.03
+1.75%
Follow TXMD
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
49.32 | 0.00 | 121.69 | 0.00 |
P/S ratio |
4.47 | 6.24 | 6.97 | 7.82 | |
P/FCF ratio |
7.27 | 9.07 | 10.06 | 9.40 | |
P/Operating CF |
12.51 | 50.29 | 24.77 | 32.84 | |
P/B ratio |
0.46 | 0.70 | 0.87 | 0.94 | |
Price to Tangible BV |
0.53 | 0.82 | 1.00 | 1.09 | |
EV/Sales |
96.83 | 91.57 | 83.60 | 86.16 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
129.16 | 112.76 | 103.85 | 90.97 | |
EV/FCF |
157.40 | 133.16 | 120.66 | 103.54 | |
Quick Ratio |
2.18 | 2.30 | 2.37 | 2.52 | |
Current Ratio |
2.93 | 3.02 | 3.11 | 3.22 | |
Net Debt/EBITDA |
9.29 | 11.58 | 21.15 | 9.65 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.07 | 0.08 | 0.09 | 0.09 | |
Operating CF/Net income |
6.57 | (0.61) | 9.94 | 5.03 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(287.33) | — | — | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
193.62% | 256.66% | 186.88% | 181.47% | |
Intangible Assets out of Total Assets |
0.10 | 0.10 | 0.10 | 0.09 | |
Share Based Compensation of Revenue |
0.00% | 5.71% | 0.28% | 0.46% | |
Graham Net Nets |
0.26 | 0.19 | 0.20 | 0.22 | |
Graham Number |
1.08 | 0.00 | 0.93 | 0.00 | |
Earnings Yield |
2.03% | (3.28%) | 0.82% | (1.06%) | |
Free Cash Flow Yield |
13.76% | 11.02% | 9.94% | 10.64% | |
Revenue per Share |
0.07 | 0.08 | 0.06 | 0.08 | |
Operating CF per Share |
0.09 | 0.03 | 0.08 | 0.07 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.09 | 0.03 | 0.08 | 0.07 | |
Cash per Share |
0.61 | 0.65 | 0.73 | 0.79 | |
Shareholders Equity per Share |
2.37 | 2.32 | 2.33 | 2.34 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.37 | 2.32 | 2.33 | 2.34 | |
Free Cash Flow |
1.00 | 0.38 | 0.94 | 0.78 | |
Working Capital |
9.56 | 9.66 | 10.35 | 11.12 | |
Net Current Asset Value |
3.28 | 3.67 | 4.66 | 5.72 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
3.49 | 3.54 | 3.10 | 3.57 | |
Average Payables |
0.25 | 0.32 | 0.10 | 0.41 | |
Average Assets |
39.11 | 38.24 | 37.91 | 38.02 | |
Average Common Equity |
27.27 | 27.12 | 26.86 | 27.21 |
Columns are period end dates